Purpose: Bilateral deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) reduces seizures and is relatively safe but may be accompanied by complaints of memory problems and depression. This study examined incidence of memory and depression adverse events (AE) in the SANTE study blinded phase and their relationship to objective neurobehavioral measures, baseline characteristics, quality of life and long-term neurobehavioral outcome. Method: The neurobehavioral AE and neuropsychological data from a previously reported prospective randomized trial (SANTE) were analyzed. Reliable change indices (RCI) were calculated for memory and mood measures. Analyses examined relationships among AEs, RCIs, demographic and seizure variables, and long-term neurobehavioral outcome. Results: No significant cognitive declines or worsening of depression scores were observed through the blinded phase or in open-label at 7-years. Higher scores were observed at 7 years on measures of executive functions and attention. Depression and memory-related AEs were not associated with reliable change on objective measures or 7-year neurobehavioral outcome. The AEs were without significant impact on life quality. Memory and depression AEs were not related to demographic or seizure characteristics, change in seizure frequency, frequency of AE or depression report. Conclusion: Bilateral ANT DBS was associated with subjective depression and memory AEs during the blinded phase in a minority of patients that were not accompanied by objective, long-term neurobehavioral worsening. Monitoring and neuropsychological assessment of depression and memory are recommended from a theoretical standpoint and because more memory and depression AEs occurred in the active stimulation than control group.
Introduction
Approximately a third of persons with epilepsy continues to experience seizures despite treatment with anti-seizure drugs (ASDs) [1, 2] . Of those with refractory epilepsy undergoing resection surgery, it is estimated that 32% of those with brain lesions and 57% of those without lesions are still not seizure free after surgery [3] . In addition, many patients with refractory partial epilepsy cannot undergo resective surgery due to poorly localized or multifocal onsets. This large prevalence of refractory epilepsy has profound implications for neurobehavioral morbidity because chronic epilepsy is associated with a host of cognitive and neurobehavioral deficits [4] and perhaps even cognitive disadvantage during aging [5] . Chronic partial seizures, specifically, are associated with declines in memory and executive functions [6] .
Consequently, new, efficacious and safe therapies might, among many other benefits, ameliorate or prevent neurobehavioral morbidity associated with epilepsy in proportion to the extent that seizures cause cognitive problems.
One therapy involves electrical stimulation of the anterior nuclei of the thalamus (ANT). Following the success of initial unblinded studies [7] [8] [9] [10] [11] [12] , the initial blinded phase [13] and 5-year follow-up [14] results of a controlled, randomized trial (SANTE) of bilateral ANT deep brain stimulation (DBS) in 109 randomized (110 implanted) subjects were reported. At 5 years, the median percentage seizure reduction was 69% relative to baseline and during the 5 years 16% of subjects were seizure-free for 6 months or more. Given the role of the anterior thalamus in the Papez circuit (notably its inputs from hippocampus via the mammillothalamic tract and outputs to cingulate gyrus and downstream limbic structures via cingulum), and the observation of reversible memory impairment after high frequency stimulation of amygdala-hippocampus [15] , it is important to evaluate the neurobehavioral safety of ANT stimulation. This evaluation is especially pertinent regarding episodic memory, complex attention, executive function, and emotion (depression/dysphoria).
One small study of 9 patients who underwent bilateral ANT stimulation and pre-surgical baseline and repeat neuropsychological testing at least 1 year after surgery reported improvements in the group as a whole in verbal memory and verbal fluency [16] . In the SANTE trial, there were no significant differences in objective neuropsychological test scores for mood and cognition between active and control groups at the end of the blinded phase; however, self-reported depression and memory adverse events (AEs) were more frequent in the active as compared to the control group [13] . Further, compared to baseline, there were no significant declines across the five years in objective test scores in any domain of cognition assessed, including verbal and visual memory, attention, executive function and expressive language [14] . Indeed, significant gains were seen in composite scores of attention and executive functions and subjective cognitive (executive) function. Although no significant verbal or visual memory score changes were observed at the group level, subjective complaints of at least transient memory dysfunction were common among individuals (25.5% in 5 years). Similarly, despite observed gains on self-report scales of symptoms of depression, anxiety, and overall mood disturbance, depression events were reported in 32.7% of subjects in 5 years. It is emphasized that AE reports of depression do not necessarily imply a syndromal depression. Specifically, persons may report that they experience "depression" when they perceive themselves having individual or several symptoms (e.g., dysphoria, anhedonia, pessimism, hopelessness, sleep disturbance, etc.), but such symptoms need not meet criteria for the diagnosis of a depressive syndrome (disorder) per Diagnostic and Statistical Manual (DSM) [17] criteria. An important aspect of depression is its association with suicidality. Over 5 years, 8.2% of individuals in the SANTE trial reported suicidal ideation and there was one completed suicide, unrelated to the device or stimulation.
Given the apparent contradiction between objective neuropsychological evaluation findings at the group level and AE reports at the individual level, this study focuses on individual patient outcomes, especially during the blinded phase, in order to put into perspective the clinical impact of subjectively reported memory or mood problems. Individual neuropsychological change is quantified via the reliable change (RC) index and the relationship between RC changes and AE reports concerning mood and memory are evaluated. The potential clinical relevance of neurobehavioral changes are assessed by comparing quality of life (QOL) using the Quality of Life in Epilepsy Inventory (QOLIE-31) in those with and without neurobehavioral adverse events.
Potential correlates of memory and depression AEs are explored, including pre-operative neurobehavioral morbidity and demographic variables. The time and course of depression and memory complaints during the study are examined. If events were similarly frequent in the active stimulation vs. implanted but not stimulated control groups during the 3-month-blinded phase, it might be that surgical implantation impacted cognition or the subjective perception of impaired cognition (i.e., produced a nocebo effect). Following the blinded phase, clustering of events early in the study might suggest a stimulation-related effect; whereas, a more random scattering of events over the study duration, or a late occurrence raises the possibility that events at different time points might have different causes and associations with various potentially mediating or moderating variables, such as seizure occurrence or frequency, medication changes, or psychosocial factors. An examination of the temporal contiguity between depression and memory events is of importance given the oft-reported much stronger relationship by which depression is associated with memory impairment [18] [19] [20] [21] . Finally, the study presents neuropsychological test scores from baseline compared to long term follow-up at 7 years to further address stability of neuropsychological findings.
Material and methods
Full details of the SANTE trial design, including inclusion and exclusion criteria, have been reported [13] . Briefly, subjects were 18-65 years old and had at least 6 partial seizures per month that had proved refractory to pharmacotherapy (with at least 3 ASDs). Neurobehavioral exclusion criteria included intelligence quotient (IQ) <70, inability to take the neuropsychological tests, nonepileptic seizures, and any of the following in the 5 years preceding baseline evaluation: history of substance abuse, psychiatric illness hospitalization, suicide attempt, or symptoms of psychosis (hallucinations, delusions) not related to medication or an ictal or post-ictal state.
After 3 months during which ASDs remained stable, subjects had the device implanted with lead location verified by MRI. One month after implantation, subjects were randomized to stimulation (n = 54) or no stimulation (n = 55) at fixed device settings (5 V or 0 V, 90 ms, 145 Hz), on an intermittent stimulation schedule (1 min "on" then 5 min "off"). After 3 months of blinded treatment, all subjects received stimulation (limited range of parameters) from Month 4 to Month 13 in an unblinded fashion. Neuropsychological evaluation during that time was conducted per the schedule in Fig. 1 and annually thereafter. The neuropsychological assessment time points were chosen a priori with several considerations in mind and to allow a variety of inferences to be made about the neurobehavioral impact of surgery and DBS. Initial IQ assessment at Week-12 was designed only to determine whether the IQ inclusion criterion was met. The baseline neuropsychological assessment (Week-4) was timed to balance several competing issues: maximization of test-retest (baseline to post-implantation) interval to minimize practice effects, while minimizing the testretest interval to minimize the likelihood that factors extraneous to surgical implantation affect test score changes, and to minimize pre-surgical anxiety (which likely peaks close to surgery) effects on testing. The second (Week 4, operative phase, post-implantation assessment without stimulation) was included to distinguish potential neurobehavioral effects of surgery vs. stimulation via comparison to baseline and to provide a measure close in time before stimulation onset to most accurately compare neurobehavioral impact of DBS by comparing change in the active and control groups from operative phase to end of blinded phase. The third assessment at the end of the 3-month blinded stimulation phase (Month 4) permits comparison of change from baseline and operative phase in the active and control groups and permits inferences about effects of surgery, potential recovery from surgical effects, and the effects of stimulation and the interaction between surgery and subsequent stimulation. The fourth assessment (Month 7) allows for replication of Month 4 findings in the active group in the by now 3-month stimulated control group. Additional assessments were performed at Month 13 and annually thereafter through 7 years of post-implant follow-up.
Neuropsychological measures
Several factors were considered in test selection: (1) test validity for use with persons with epilepsy; (2) patient acceptability; (3) availability of alternate forms; (4) time required; (5) ease of administration and scoring; and (6) cognitive and emotional functions that might be expected to be affected given the neuroanatomical target of intervention. Timing of test administration is listed in Fig. 1 , and brief test descriptions are provided in Supplemental Table S1 .
Average test scores are presented for each test at baseline and 7 years. Because evaluations utilized a variety of test instruments, most of which yield many scores, data reduction was planned a priori so as to facilitate meaningful analyses and to reduce the statistical Type I error rate. The most important standardized scores from the tests were converted to the same metric (mean 50; standard deviation 10; i.e., T scores) and averaged to calculate composite scores in each neurobehavioral domain. These composites were used to compare performance across time within a group and between the stimulation and control groups through the blinded phase. Domain composite scores were derived from the following test scores: Verbal Memory: CVLT-II [22] Note that both immediate and delayed recall scores were used in memory composites; although the scores are typically correlated, delayed recall impairments can occur despite intact immediate recall and it was deemed important to capture such impairments. Quality of life was assessed with the QOLIE-31 [25] .
Statistical analyses
Statistical tests were examined for significance at the twotailed 0.05 level with no adjustments for multiple comparisons.
SAS software (version 9.2; SAS Institute, Cary, NC) was used for all analyses. In addition to typical summary statistics, Pearson correlation was used to assess relationship, Fisher's exact test was used to calculate p-values related to binary/categorical outcomes and a t-test or Wilcoxon rank sum test was used to assess continuous change from baseline outcomes, as appropriate.
One method to determine the meaningfulness of a change in an individual's neuropsychological test scores over time is by comparison of the individual's specific change score to an adjusted 90% reliable change confidence interval (RCI), calculated from the control group data and adjusted by adding the mean to each 90% confidence bound [26] . Thus, the adjusted RCI allows estimation of measurement error surrounding test-retest differences and thereby an inference whether the change score is meaningful (exceeds what might be expected on the basis of measurement error and practice (test-retest) effects alone and is thus unlikely to be a chance phenomenon). The scores for which RCIs were computed are those test scores previously used to calculate verbal and visual memory composites and those most relevant to depression AEs. Calculation of clinically meaningful QOL changes was based on published values of minimum clinically significant change for the QOLIE-31 [27] .
Results

Incidence of depression, memory, and other adverse events during blinded phase
Depression was reported by 8 subjects in the active (14.8%) and 1 subject (1.8%) in the control group (p = 0.016) (Supplemental Table S2 ), while 7 subjects (13.0%) in the active and 1 subject in the control group (1.8%) reported a memory AE (p = 0.032) (Supplemental Table S3 ). The next most frequent neurobehavioral AEs were "confusional state" (7.4% active, 0% control) and "anxiety" (9.3% active, 1.8% control). These AEs occurred at lower frequencies than memory and depression AEs and the differences between groups did not attain statistical significance. No other significant differences in rate of neurobehavioral AEs were observed in the two groups. For this reason, memory and depression were selected for more in depth analyses in this study.
Of the depression AEs, one was deemed serious and none of the memory AEs were serious. The one serious depression event occurred in a subject with a history of depression who required hospitalization twice in the 4 months following the blinded phase, once for 10 days and once for 3 days. Half (4/8) of the active group depression events resolved, in an average of 76 days, and all memory events resolved, in an average of 103 days. There was minimal overlap between those complaining of depression and memory impairment during the blinded phase: the 9 depression and 8 memory AEs were attributable to 15 subjects, meaning only 2 subjects complained of both AEs. The mean total number of nondepression and non-memory events reported by those complaining of depression (2.5) vs. not (1.7) did not differ significantly (p = 0.292). Similarly, mean total AE complaints among those reporting memory problems (2.3) vs. not (1.8) did not differ (p = 0.281). These findings suggest that the increased active group rate of depression and memory AEs were not simply related to a tendency to report more AEs (i.e., a negative response bias).
Examination of factors
Although 6 of 8 subjects reporting depression AEs in the active group had a prior history of depression diagnoses, none of these subjects complained of depression during the baseline observation period or operative phases. Among other subjects, one made a suicide attempt and one had suicidal ideation during the baseline phase and neither was implanted. There was no difference in the percentage of subjects with baseline depression history between the active (51.9%) and control (40.0%) groups (p = 0.251).
Among those reporting a memory AE during the blinded phase, none had made a similar report during baseline or operative phase. Nonetheless, the baseline average memory scores of the entire group of subjects is mildly impaired (about 1-1.5 standard deviations below normative means). Furthermore, at baseline, 50% of those with blinded phase memory AEs had at least a mildly impaired range score (T < 40) on either BVMT-R immediate (Total) or Delayed Recall, as did 68% of the remaining 101 subjects. At least mildly impaired (T < 40) verbal memory (CVLT-II Total or Delayed Recall) was evident in 38% of those with blinded phase memory AEs, and in 64% without such AEs. An examination of the reverse relationship is instructive with regard to whether those with prior history of depression or baseline memory problems were more likely to report similar AEs in the blinded phase. Of those with a history of depression (n = 50 of 109), 6 (12%) had a blinded phase event (Supplemental Table S4 ). Of the remainder without a history of depression (n = 59), 3 had a blinded phase event (5%). Of those with baseline impaired visual memory (n = 73 of 109), 4 (5%) had a blinded phase memory AE, but 4/36 (11%) without baseline impairment reported a memory AE. A similar pattern held for verbal memory: 3/68 (4%) with baseline impairment reported a memory AE, but 12% (5/41) without baseline verbal memory impairment reported a memory AE during the blinded phase. Thus, whilst prior depression diagnosis might heighten risk of a depression AE within 4 months of surgery, those without presurgical memory impairment may be more apt to report memory AEs.
Demographic and seizure characteristics of those with and without depression and memory AEs
There were no differences among those with and without memory and depression AEs in gender, age, duration of epilepsy, or seizure frequency at baseline (Supplemental Table S4 ). Furthermore the groups did not differ in the number of ASDs at baseline or prior history of epilepsy surgery or vagus nerve stimulation. Specific reports of a large variety of medical conditions were not associated with those not reporting a depression AE and those who did (Supplemental Table S4 ). Those reporting a memory impairment AE were more likely to have a history of back pain (p = 0.012) or insomnia (p = 0.042) compared to those not reporting an AE.
Depression may worsen or improve with changes in seizures. The median percent change in seizure frequency from baseline for those active group subjects reporting depression was À63.1%, compared to À30.5% for those who did not report depression, a non-significant difference (p = 0.105). The median percent change in seizure frequency from baseline for those active group subjects reporting memory impairment was À50.9%, compared to À31.1% for those who did not report memory impairment, also a nonsignificant difference (p = 0.489).
Relationship between depression and memory impairment AEs in the blinded phase
The number of persons reporting or not reporting a memory AE and those reporting or not reporting a depression AE are presented in Supplemental Table S5 for those in the active group and for all randomized subjects; neither indicates a significant association in subjects reporting each type of event. No significant differences in the long term median scores on subjective depression and cognition measures (POMS) and visual memory change were observed among those subjects in the active group reporting and not reporting a memory AE during the double blind phase (Table 1) . Interestingly, those complaining of a memory AE during the double blind phase in the active group actually showed greater improvement from baseline to Month 4 in the verbal memory composite score than the group without such complaints (p = 0.029). These results are consistent when all randomized subjects are considered (p = 0.013). No differences in subjective depression, cognition, or verbal and visual memory change from baseline to Month 4 were seen in those reporting or not reporting a depression AE in the active group or in all randomized subjects. Correlational analyses similarly revealed only a significant relationship between memory complaint and verbal memory score change (the positive correlation indicates an association between more complaints and paradoxical improvements in verbal memory scores from baseline to Month 4; r = 0.32, p = 0.018) ( Table 2 ). A similar relationship was observed in all randomized subjects (r = 0.25, p = 0.012).
Reliable change in depression and memory scores from baseline to the end of the blinded phase
The statistics relevant to RCI calculation are presented in Table 3 . There were no significant differences between the active and control groups in the frequencies with which test score changes exceeded the reliable change confidence band in selfreported depressive symptoms (POMS Depression), subjective cognitive problems (POMS Confusion-Bewilderment), verbal memory (CVLT-II immediate recall across 5 trials and delayed recall), and visual memory (BVMT-R immediate recall across 3 trials and delayed recall). Although frequencies of reliable worsening were higher in both the active and control groups using the adjusted RCI rather than RCI (which would be expected because the practice effect accounted for is positive and a higher mean score is expected on re-test), there remained no between group differences in change.
For those subjects having worsening per RCI on a depression symptom self-report scale (POMS), 2/4 in the active group, but 0/ 3 in the control group also reported a depression AE during the blinded phase. Conversely, of the subjects reporting depression AEs during the blinded phase, 2/8 in the active group and 0/1 in the control group reported worsening per RCI or adjusted RCI. Abbreviations: S diff = standard error of the difference. There was poor agreement between AE report and either objective verbal memory or visual impairment (none of those identified as worsened by RCI or adjusted RCI reported an AE and vice versa). Even more striking perhaps is the observation that none of those 5 subjects (3 active, 2 control) showing a marked worsening via a subjective cognitive function scale (POMS Confusion-Bewilderment) reported an AE related to cognition.
Relationship between baseline neuropsychological scores and reliable change
There was no clear relationship between baseline score and either worsening or improvement on tests, suggesting it is difficult to predict significant neuropsychological change from baseline examination.
Impact of memory and depression AEs on quality of life
The mean improvement in QOLIE-31 between baseline and Month 4 was 4.7 points (n = 7) in the active group for persons reporting depression AEs and was 2.2 points (n = 45) for those not reporting depression events. For active group subjects reporting memory AEs, the mean improvement in QOLIE-31 from baseline was 3.6 points (n = 7), and for those not reporting memory impairment events, it was 2.3 points (n = 45). No significant difference in QOL gain (total QOLIE-31 score, with a higher score indicating better QOL) was observed between those with and without depression AEs (p = 0.523) and those with and without memory impairment AEs (p = 0.558). Similarly the proportions of persons showing no change or a gain or decrement in QOL as defined by the minimally clinically meaningful change did not differ among those with and without memory and depression AEs in the active group (Table 4 ).
7-year follow-up of neurobehavioral functioning
Seven-year follow-up data available on 67 subjects (not all had every test at both baseline and follow-up) reveal no significant cognitive declines, neurobehavioral problems (e.g., apathy, disinhibition), subjective cognitive declines, or affective distress (depressive and anxious symptoms) among the group (Table 5) . Significantly better test scores compared to baseline were observed at 7 years in immediate visual recall, design fluency, Trailmaking (Number-Letter Switching), an analog of the Stroop task (Inhibition/Switching), the Tower task (problem solving), and simple visual attention (Trailmaking Number Sequencing and Letter Sequencing).
When depression, visual memory and verbal memory scores are examined each year through year 7 for those reporting and not reporting depression (Supplemental Table S6 ) or a memory impairment event (Supplemental Table S7 ), no differences in outcome are noted.
Discussion
Although individual subjects could exhibit depression or memory adverse events, this long-term follow-up study does not support an overall deleterious effect of ANT stimulation on mood or cognition. Stimulation of the ANT to reduce focal seizures [13, 14] produced more subjective reports of depression and memory problems in the active group than in the control (implanted but not stimulated) group during the blinded phase. By contrast, objective neurobehavioral evaluation showed no baseline-treatment or placebo-active stimulation group differences. This study analyzed the depression and memory complaints in greater detail and over a longer time. Specifically, to more painstakingly address potential safety concerns, this study examined the relationship between depression and memory AEs and individual neuropsychological outcome, potential factors underlying the AEs, and their potential clinical relevance by examining impact of memory and depression AEs on quality of life and long-term (7-year) neurobehavioral outcome.
Rates of memory and depression AEs using reliable change on quantitative measures, yielded somewhat lower rates of depression than AE reports (7.4% vs. 14.8%) in the active group, and lower rates of decline on various objective memory tests (0.0%-9.3%) and subjective cognitive problems report (5.6%) than memory AEs (13.0%). The AEs were not associated with reliable change scores on objective measures of interest. In addition to the lack of objective findings, two other observations are of importance in addressing the clinical importance of the AEs. One, those reporting and not reporting AEs showed similar proportions of quality of life improvement, no change, or decrement at the end of the blinded phase, and their mean quality of life score changes did not differ significantly. Two, the neurobehavioral outcome in the long-term, did not differ among those reporting and not reporting AEs.
There are several possible reasons for the discordance between AEs and objective measures. One is that subjects are inaccurate in reporting AEs (although the fact that 5/8 depression AEs and 2/ 7 memory AEs needed treatment or stimulator adjustment suggests that this cannot be the sole explanation). Alternatively, although the terms reported in this study capturing memory and depression AEs showed minimal variation, a range of AEs may be grouped under the reportable terms and this heterogeneity may dilute the construct being examined. Indeed, current methods of screening for and collecting AE information regarding neurobehavioral issues may be less than optimally reliable. Subjective reports of "depression" may never be followed by a formal diagnostic process using standardized criteria. Other explanations include the possibility that several AEs started and resolved between neuropsychological assessments, reducing the power to detect relationships among AEs and objective neurobehavioral measures. In addition, although memory measures utilized alternate forms (2 for verbal memory and 6 for visual memory), it remains possible that practice effects masked declines. This explanation, however, is not entirely plausible because we also examined relationships between AEs and practice effect-corrected RCIs. Finally, subjects with seizure reduction and/or improved cognition may become more aware of their cognitive difficulties. Thus, even though they show gains on cognitive measures, they following that gain may actually be more aware of problems, especially if in a more challenging environment. This is supported by the observation in our study, despite absence of significant findings, that those complaining of memory AEs, if anything, tended to have improved verbal memory scores. Lack of statistical power may also have hindered our attempts to identify historical, demographic, and seizure-related factors that might be associated with AEs. Nonetheless, those with a history of depression may be more at risk of exacerbations after treatment. Six out of 8 subjects with depression AEs in the blinded phase had a history of diagnosed depression prior to treatment. The same may not be true for memory: 50% of those with memory AEs had at least mildly impaired visual memory scores at baseline, whereas 68% of remaining subjects did. Similarly, lack of power may explain why we did not find an association between memory AEs or memory test scores and depression, an association that has been documented in several studies [18, 20] . One other possible mechanism for neuropsychiatric changes after ANT DBS is sleep disruption [28] ; unfortunately sleep data that might address this possibility were not collected as part of this study. Despite lack of cognitive decline at the group level and the relative infrequency of clinically meaningful memory and depression AEs after ANT DBS, these neurobehavioral domains should be routinely monitored and neuropsychologically evaluated before and during deep brain stimulation of ANT. First, during the blinded phase subjective depression and memory AEs occurred more frequently in the active than control group. Second, literature supports the role of the Circuit of Papez, of which ANT is an integral node, in the regulation of mood and memory [29] . Although human evidence of the role of ANT in mood and memory comes primarily from other clinical populations, such as stroke [30] , limited data from humans suggest ANT DBS could affect memory by impacting electrophysiologic synchronization [31] . Stimulation of ANT might in theory impair, enhance or show mixed effects on memory depending upon stimulation parameters and circumstances during testing. Indeed, one small study found improvements in memory one year after ANT DBS [16] . While it is encouraging that neurobehavioral functions showed little change or improvement per objective tests over 7 years in this study, this study does not have a long-term control group. Future work is thus needed to determine whether gains on attention and executive function tests (which are accompanied by improvement in selfreported frontal functions) are merely practice effects.
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